National Pension Service Has $81.52 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

National Pension Service raised its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 4.9% during the second quarter, Holdings Channel reports. The institutional investor owned 2,406,013 shares of the company’s stock after buying an additional 112,357 shares during the quarter. National Pension Service’s holdings in Teva Pharmaceutical Industries were worth $81,516,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Aster Capital Management DIFC Ltd bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $25,000. Cornerstone Planning Group LLC increased its position in Teva Pharmaceutical Industries by 547.1% in the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after purchasing an additional 755 shares during the period. Allworth Financial LP increased its position in Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after purchasing an additional 329 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after purchasing an additional 345 shares during the last quarter. Finally, Global Retirement Partners LLC raised its holdings in Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after purchasing an additional 292 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA opened at $37.01 on Friday. The firm’s 50 day simple moving average is $34.91 and its 200 day simple moving average is $33.37. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $18.21 and a fifty-two week high of $38.37. The company has a market capitalization of $43.13 billion, a price-to-earnings ratio of 61.68, a P/E/G ratio of 4.53 and a beta of 0.87. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The firm had revenue of $4.14 billion during the quarter. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on TEVA shares. Weiss Ratings lowered shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a report on Friday, September 4th. Leerink Partners began coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday. They issued an “outperform” rating and a $45.00 price objective on the stock. Finally, Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research report on Tuesday, July 28th. Ten analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and a consensus price target of $43.10.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.